Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

JAMA Netw Open · 2026 · PMC13084435 · PMID 41984479

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an observed trendno p-value reported

The CheckMate 214 study 2 , 16 required more than 8 years of follow-up to demonstrate a crossover in survival curves among patients with favorable risk, with an observed trend toward better outcomes with IO-IO therapy that was not statistically significant.

also in 258 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.